PFE-360(PF-06685360) is a selective small molecule kinase inhibitor of LRRK2 that can cross the blood-brain barrier.

 

Brand: BCM

 

Target: LRRK2

 

Signaling Pathways: Autophagy

 

In Vivo: PFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment effectively reduces the LRRK2-pSer935/total LRRK2 ratio. It has no significant adverse effects.

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

Isomeric SMILES: CN1C=C(C=C1C#N)C2=CNC3=C2C(=NC=N3)N4CCOCC4  

 

InChIKey: IYQTYHISVSPMSU-UHFFFAOYSA-N  

 

InChI: InChI=1S/C16H16N6O/c1-21-9-11(6-12(21)7-17)13-8-18-15-14(13)16(20-10-19-15)22-2-4-23-5-3-22/h6,8-10H,2-5H2,1H3,(H,18,19,20)

 

Attribute
[Chem Name]	1-methyl-4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrrole-2-carbonitrile
[Synonym]	PFE-360; PF-06685360
[CAS No.]	1527475-61-1
[Formula]	C16H16N6O
[Molecular]	308.34
[Form]	White to beige powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag